NCT03509272 LimPrOn: Limburg Pre-eclampsia Investigation
| NCT ID | NCT03509272 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hasselt University |
| Condition | Pregnancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2016-05 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,000 participants in total. It began in 2016-05 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Multiple adaptations at the cardiovascular system occurs during pregnancy. In the pregnancy condition pre-eclampsia (PE), this adaptations are abnormal. Five to eight percent of all pregnant women worldwide will develop PE. PE is a pregnancy condition which is characterized with a high blood pressure (\>140/90 mm Hg) and the occurrence of proteinuria (\>3g/dl/24h) after 20 weeks of gestation. When untreated, this condition can have severe complications for both mother and child. It's important to monitor women with a high risk for developing PE for an early detection and treatment of this condition. For this reason, a multicenter study is set up with the following applications: 1. NICCOMO and Maternal Venous Doppler Echography: impedance cardiograph and an echography of the heart and veins. 2. Maltron: bio-electronic impedance analyze 3. Remote monitoring of the high risk patients to become a more intensive follow-up Number of inclusions: 2000 pregnant women from the prenatal consultations of eight different hospitals:
Eligibility Criteria
Inclusion Criteria: * \> 10 weeks of pregnancy, primipara and multipara Exclusion Criteria: * \< 10 weeks of pregnancy and congenital malformations of the fetus
Contact & Investigator
Dorien Lanssens, drs.
✉ dorien.lanssens@uhasselt.beWilfried Gyselaers, prof. dr.
PRINCIPAL INVESTIGATOR
Hasselt University
Frequently Asked Questions
Who can join the NCT03509272 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03509272 currently recruiting?
Yes, NCT03509272 is actively recruiting participants. Contact the research team at dorien.lanssens@uhasselt.be for enrollment information.
Where is the NCT03509272 trial being conducted?
This trial is being conducted at Bree, Belgium, Genk, Belgium, Hasselt, Belgium, Heusden-Zolder, Belgium and 4 additional locations.
Who is sponsoring the NCT03509272 clinical trial?
NCT03509272 is sponsored by Hasselt University. The principal investigator is Wilfried Gyselaers, prof. dr. at Hasselt University. The trial plans to enroll 2,000 participants.